<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0012546" disease_type="Disease or Syndrome" abbrv="">Diphtheria</z:e> fusion proteins are a novel class of agents for the treatment of chemotherapy resistant <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We prepared <z:e sem="disease" ids="C0012546" disease_type="Disease or Syndrome" abbrv="">diphtheria</z:e> toxin/urokinase fusion protein (DTAT) composed of the amino terminal fragment of the urokinase-type plasminogen activator (uPA) fused to the catalytic and translocation domains of <z:e sem="disease" ids="C0012546" disease_type="Disease or Syndrome" abbrv="">diphtheria</z:e> toxin (DT) and assessed its activity on leukemic cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>The number of uPA receptors (uPAR or CD87) was measured using a phycoerythrin conjugated monoclonal antibody to CD87 and flow cytometry </plain></SENT>
<SENT sid="3" pm="."><plain>Seven of 23 cell lines (30%) showed CD87 expression (&gt; or =5000 receptors/cell) </plain></SENT>
<SENT sid="4" pm="."><plain>DTAT cytotoxicity (IC(50)&lt; or =30pM) was observed in <z:hpo ids='HP_0000001'>all</z:hpo> seven of these samples and none of the 16 samples with low or absent CD87 expression </plain></SENT>
<SENT sid="5" pm="."><plain>There was a significant correlation between DTAT sensitivity and CD87 density (P=0.0007) </plain></SENT>
<SENT sid="6" pm="."><plain>These results show that specific CD87 binding is one factor important in the sensitivity of patient's leukemic blasts to DTAT and demonstrate for the first time that the CD87/uPAR can be used as a target for fusion protein therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>